Tolerance induction for food allergy using immunoglobulin/histamine complex A case report
Main Article Content
Keywords
IgE-mediated food allergy, Tolerance, Atopic dermatitis, chronic spontaneous urticaria, immunoglobuolin/histamine complex
Abstract
Food allergy is defined as an immune-mediated adverse reaction to dietary proteins and is a major health problem with an increasing prevalence. Immunoglobulin/histamine complex (IHC) is an anti-allergy therapeutic that acts primarily by reducing histamine levels (histaminopexy). A 5-year-old male Korean patient with a food allergy was transferred for immunotherapy. Open food challenge (OFC) for wheat before treatment revealed positive reactions after challenge with 0.5g of wheat. Under a diagnosis of food allergy for wheat, allergic rhinitis, and atopic dermatitis, treatment with HistobulinTM (Green Cross PD, Korea), an IHC preparation, was initiated. After 23 injections, the patient did not exhibit any adverse reaction after the intake of 60 g of wheat in the OFC. Specific IgE levels and skin reactivities for wheat also decreased after IHC therapy. A 40-year-old female Korean patient presented with severe generalized urticaria, severe itching, and even whole body prickling immediately after every intake of shrimp or crab over 10 years; she also had allergic rhinitis. Basic allergy lab and skin prick testing results showed no abnormal findings, but OFC for shrimp and raw crab (both at 0.5 g) produced generalized urticaria, rashes, and itching immediately after intake. Under a diagnosis of chronic urticaria, allergic rhinitis, and food allergy to crab and shrimp, IHC therapy was initiated. After 86 injections of HistobulinTM, the patient did not show any allergy reaction to shrimp or crab after the intake of 10 g of raw shrimp or 10 g of raw crab. IHC treatment successfully induced food allergen tolerance in a nonallergen-specific manner. © 2026 Codon Publications. Published by Codon Publications.
References
2. Sicherer SH, Sampson HA. Food allergy: a review and update on epidemiology, pathogenesis, diagnosis, prevention, and management. J. Allergy Clin. Immunol. 2018:141;41–58. https://doi.org/10.1016/j.jaci.2017.11.003
3. Kivity S. Adult-onset food allergy. Isr. Med. Assoc. J. 2012;14:70–2.
4. Yu W, Freeland DMH, Nadeau KC. Food allergy: immune mech-
anisms, diagnosis and immunotherapy. Nat. Rev. Immunol. 2016;16:751–65. https://doi.org/10.1038/nri.2016.111
5. Riggioni C, Oton T, Carmona L, Du Toit G, Skypala I, Santos AF. Immunotherapy and biologics in the management of IgE-mediated food allergy: systemic review and meta-analysis of efficacy and safety. Allergy. 2024;79:2097–127. https://doi.org/10.1111/all.16129
6. Alexandra FS, Carmen R, Ioana A, Cezmi AA, Mubeccel A, Alberto A-P, et al. EAACI guidelines on the management of IgE-mediated food allergy. Allergy. 2025;80:14–36.
7. Kazmi W, Berin MC. Oral tolerance and oral immunotherapy for food allergy: evidence for common mechanisms? Cell Immunol. 2023;383:104650. https://doi.org/10.1016/j. cellimm.2022.104650
8. Worm M, Francuzik W, Dölle-Bierke S, Alexiou A. Use of biologics in food allergy management. Allergol. Sel. 2021;5:103– 7. https://doi.org/10.5414/ALX02141E
9. Leung DYM, Sampson HA, Yunginger JW, Burks AW, Schneider LC, Wortel CH, et al. Effect of anti-IgE therapy in patients with peanut allergy. N. Engl. J. Med. 2003;348:986–93. https://doi.org/10.1056/NEJMoa022613
10. Brandström J, Vetander M, Sundqvist AC, Lilja G, Johansson SGO, Melén E, et al. Individually dosed omali-zumab facilitates peanut oral immunotherapy in peanut allergic adolescents. Clin Exp Allergy 2019;49:1328–41. https://doi.org/10.1111/cea.13469
11. Parrot JL, Laborde C. The histamine-fixing power of blood serum; its modification after an injection of normal human serum or of an azoprotein of histamine. J. Physiol. (Paris) 1954;46:492–5.
12. Gushcin IS, Luss LV, Il’ina NI, Larina ON, Pakhomova LA. Therapeutic effectiveness of histaglobin preparations in patients with allergic rhinitis and chronic urticaria. Ter. Arkh. 1999;71:57–62.
13. Jankowska R, Małolepszy J, Nowak I. Influence of histaglobin therapy on skin tests and clinical symptoms in patients with atopic bronchial asthma. Pneumonol. Alergol. Pol. 1992;60:69–72.
14. Salman A, Demir G, Bekiroglu N. The impact of omalizumab on quality of life and its predictors in patients with chronic spontaneous urticaria: real-life data. Dermatol. Ther. 2019;32:e12975. https://doi.org/10.1111/dth.12975
15. Noh G. Histobulin as a complementary but essential therapeutic for intravenous immune globulin therapy of Pfeiffer Weber-Christian disease with multiple allergic diseases and its effects on allergic disease: a case report. Clin. Case Rep. 2020;29:966– 72. https://doi.org/10.22541/au.160188133.36220171
16. Noh G, Lee JH. Oral tolerance induction for human food allergy. Inflamm. Allergy Drug Targets. 2012;11:131–42. https://doi.org/10.2174/187152812800392869
17. Kim JH, Shin IS, Lee YK, Oh HJ, Ban SJ. Improved HPLC method using 2,3-naphthalenedicarboxaldehyde as fluorescent labeling agent for quantification of histamine in human immunoglobulin preparations. Osong Public Health Res. Perspect. 2011;2:127–134. https://doi.org/10.1016/j. phrp.2011.07.003
18. Sprikkelman AB, Tupker RA, Burgerhof H, Schouten JP, Brand PL, Heymans HS, et al. Severity scoring of atopic dermatitis: a comparison of three scoring systems. Allergy. 1997;52:944– 9. https://doi.org/10.1111/j.1398-9995.1997.tb01255.x
19. Jariwala SP, Monday H, de Asis ML, Fodeman J, Hudes G, de Vos G, et al. The urticaria severity score: a sensitive questionnaire/index for monitoring response to therapy in patients with chronic urticaria. Ann. Allergy Asthma Immunol. 2009;102:475–82. https://doi.org/10.1016/S1081-1206(10)60120-2
20. Di Bona D, Plaia A, Leto-Barone MS, Di Lorenzo G. Efficacy of subcutaneous and sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: a meta-analysis-based comparison. J. Allergy Clin. Immunol. 2012;5:1097-107. https://doi.org/10.1016/j.jaci.2012.08.012
21. Klimek L, Schendzielorz P, Pinol R, Pfaar O. Specific subcutaneous immunotherapy with recombinant grass pol-len allergens: first randomized dose-ranging safety study. Clin. Exp. Allergy. 2012;42:936–45. https://doi.org/ 10.1111/j.1365-2222.2012.03971.x
22. Wood RA. Oral immunotherapy for food allergy. J. Investig. Allergol. Clin. Immunol. 2017;27:151–9. https://doi.org/ 10.18176/jiaci.0143
23. Hise K, Rabin RL. Oral immunotherapy for food allergy— a US regulatory perspective. Curr. Allergy Asthma Rep. 2020;20:77. https://doi.org/10.1007/s11882-020-00973-x
24. Noh G, Lee SS. A pilot study of interferon-gamma-induced specific oral tolerance induction (ISOTI) for immunoglobulin E mediated anaphylactic food allergy. J. Interferon Cytokine Res. 2009;29:667–75. https://doi.org/10.1089/jir.2009.0001
25. Mottard L. A special immunotherapeutic practice: polydesen-sitisation or simultaneous multiple desensitisations. A 30-year experience. Rev. Med. Liege. 1990;45:638–48.
26. Pichler WJ. Specific and nonspecific (anti-IgE) immunotherapy of allergic diseases. Ther. Umsch. 2001;58:329–36. https://doi.org/10.1024/0040-5930.58.5.329
27. Lee JH, Noh G. Polydesensitisation with reducing elevated serum total IgE by IFN-gamma therapy in atopic dermatitis: IFN-gamma and polydesensitisation (PDS). Cytokine. 2013;64:395–403. https://doi.org/10.1016/j.cyto.2013.05.011
28. Kim HS, Noh G. Effects of immunoglobulin/histamine com-plex in chronic spontaneous urticaria focusing on remission induction. Allergy. 2022;77:2846–8. https://doi.org/10.1111/ all.15381
29. Qin L, Tang LF, Cheng L, Wang HY. The clinical signifi-cance of allergen-specific IgG4 in allergic diseases. Front. Immunol. 2022;13:1032909. https://doi.org/10.3389/fimmu. 2022.1032909
30. Bacher P, Scheffold A. Allergen-specific regulatory T-cell responses against aeroantigens and their role in allergy. Mucosal. Immunol. 2018;11:1537–50. https://doi.org/10.1038/ s41385-018-0038-z
31. Jansen K, Cevhertas L, Ma S, Satitsuksanoa P, Akdis M, van de Veen W. Regulatory B cells, A to Z. Allergy. 2021;76:2699– 715. https://doi.org/10.1111/all.14763
32. Schneider LC, Rachid R, Lebovidge J, Blood E, Mittal M, Umetsu DT. Pilot study of omalizumab to facilitate rapid oral desensitization in high-risk peanut-allergic patients. J. Allergy Clin. Immunol. 2013;132:1368–74. https://doi. org/10.1016/j.jaci.2013.09.046
33. MacGinnitie AJ, Rachid R, Gragg H, Little SV, Lakin P, Cianferoni A, et al. Omalizumab facilitates rapid oral desensitization for peanut allergy. J. Allergy Clin. Immunol. 2017;139:873–81. https://doi.org/10.1016/j.jaci.2016.08.010
34. Jutel M, Akdis M, Akdis CA. Histamine, histamine receptors and their role in immune pathology. Clin. Exp. Allergy. 2009;38:1786–800. https://doi.org/10.1111/j.1365-2222.2009. 03374.x
35. Izumi H, Hoshi S, Mue S, Takishima T, Sato H, Aoki T. The determination of blood histamine in asthmatic patients with a simple and sensitive method. Tohoku J. Exp. Med. 1984; 143:79–85. https://doi.org/10.1620/tjem.143.79
36. Fujisawa T, Komada M, Iguchi K, Uchida Y. Plasma histamine levels in normal and atopic children. Ann. Allergy. 1987;59:303–6.
37. Rostafinska J. [Histaminopexy]. Wiad. Lek. 1964;17:1–5.
38. Ito T, Oguro Y, Kakano T. Studies on the production of
anti-histamine antibody in the rabbits immunized with “Histobulin”: a new histamine/human-γ-globulin complex developed by authors. Japanese J. Allergology. 1971;20:285.
39. Liebhart J, Zak-Najmark T, Małolepszy J, Nadobna G, Liebhart E. Changes of histaminopexy in patients with bronchial asthma and chronic urticaria after histaglobin administration. Arch. Immunol. Ther. Exp. (Warsz) 1986;34:385–9.
40. Waldman TA, Strober W, Blaese RM. Variations in the metabolism of immunoglobulins measured by turnover rates. In: Merler E, editor. Immunoglobulins. Washington: National Academy of Science, 1970, pp. 33–51.
41. Dreskin SC, Goldsmith PK, Strober W, Zech LA, Gallin JI. Metabolism of immunoglobulin E in patients with markedly elevated serum immunoglobulin E levels. J. Clin. Invest. 1987;79:1764–72. https://doi.org/10.1172/JCI113017
42. Ayoub M, Lallouette P, Sütterlin BW, Bessler WG, Huber, M, Mittenbühler. Modulation of the Th1/Th2 bias by an immunoglobulin histamine complex in the ovalbumin allergy mouse model. Int. Immunopharmacol. 2003;3:523–39. https://doi. org/10.1016/S1567-5769(03)00031-6
43. Obara I, Telezhkin V, Alrashdi I, Chazot PL. Histamine, histamine receptors, and neuropathic pain relief. Br. J. Pharmacol. 2020;177:580–99. https://doi.org/10.1111/bph.14696